These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15057641)

  • 21. Huntington's disease - new perspectives based on neuroendocrine changes in rodent models.
    Petersén A; Hult S; Kirik D
    Neurodegener Dis; 2009; 6(4):154-64. PubMed ID: 19521064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease.
    Lee ST; Kim M
    Mech Ageing Dev; 2006 May; 127(5):432-5. PubMed ID: 16527334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Huntington's disease: new paths to pathogenesis.
    Ross CA
    Cell; 2004 Jul; 118(1):4-7. PubMed ID: 15242639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CAG repeat length on psychiatric disorders in Huntington's disease.
    Vassos E; Panas M; Kladi A; Vassilopoulos D
    J Psychiatr Res; 2008 Jun; 42(7):544-9. PubMed ID: 17610899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and systems biology approaches to Huntington's disease.
    González-Couto E
    Brief Funct Genomics; 2011 May; 10(3):109-14. PubMed ID: 21278081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative damage in Huntington's disease.
    Segovia J; Pérez-Severiano F
    Methods Mol Biol; 2004; 277():321-34. PubMed ID: 15201466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is Huntington's disease a neurological or psychiatric disorder? case report].
    Dubas-Slemp H; Tylec A; Michałowska-Marmurowska H; Spychalska K
    Psychiatr Pol; 2012; 46(5):915-22. PubMed ID: 23394029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
    Strand AD; Aragaki AK; Shaw D; Bird T; Holton J; Turner C; Tapscott SJ; Tabrizi SJ; Schapira AH; Kooperberg C; Olson JM
    Hum Mol Genet; 2005 Jul; 14(13):1863-76. PubMed ID: 15888475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
    IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Huntington's disease: progress and potential in the field.
    Stack EC; Ferrante RJ
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1933-53. PubMed ID: 18042002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapeutic targets for Huntington's disease.
    Hannan AJ
    Expert Opin Ther Targets; 2005 Aug; 9(4):639-50. PubMed ID: 16083335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amantadine in Huntington's disease: open-label video-blinded study.
    Lucetti C; Gambaccini G; Bernardini S; Dell'Agnello G; Petrozzi L; Rossi G; Bonuccelli U
    Neurol Sci; 2002 Sep; 23 Suppl 2():S83-4. PubMed ID: 12548355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiglutamate therapies in Huntington's disease.
    Kieburtz K
    J Neural Transm Suppl; 1999; 55():97-102. PubMed ID: 10335496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic role of creatine in Huntington's disease.
    Ryu H; Rosas HD; Hersch SM; Ferrante RJ
    Pharmacol Ther; 2005 Nov; 108(2):193-207. PubMed ID: 16055197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders.
    Kimura Y; Lee WC; Littleton JT
    Mini Rev Med Chem; 2007 Jan; 7(1):99-106. PubMed ID: 17266642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigational agents for the management of Huntington's disease.
    Müller T
    Expert Opin Investig Drugs; 2017 Feb; 26(2):175-185. PubMed ID: 27927041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational drugs for the management of Huntington's disease: are we there yet?
    Kulkarni P; Saxena U
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1595-603. PubMed ID: 25084527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease.
    Mo C; Hannan AJ; Renoir T
    Neurosci Biobehav Rev; 2015 May; 52():178-92. PubMed ID: 25770041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.